Drugs / VT3989
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04665206 | Mar 2021 → Nov 2029 expected | mesothelioma, non-small cell lung carcinoma | Vivace Therapeutics, Inc | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07824986 | Dec 2026 → May 2028 expected | pleural mesothelioma | Vivace Therapeutics, Inc | Not yet recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-08-26 | Vivace Therapeutics, Inc | Vivace Therapeutics Strengthens Leadership Team as It Prepares to Advance VT3989, the First TEAD Inhibitor to enter Phase 3 Clinical Trials, as the Leading Treatment for Mesothelioma vivacetherapeutics.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VT3989 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04665206 ↗ |
| Action | Inhibit | “VT3989, a first-in-class potent oral TEAD palmitoylation inhibitor, disrupts YAP transcriptional activity.” PMID 41111090 ↗ Oct 2025 |
| Route | Oral | “VT3989 will be administered orally” NCT07824986 ↗ |